Early diagnosis of cognitive impairment in the elderly with the focus on Alzheimer's disease

Journal of Neural Transmission

Volumn 105, Issue 8-9, 1998, Pages 773-786

  Gottfries, C G ^a   Lehmann, W ^a   Regland, B ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Alzheimer's disease; Biochemical markers; Cognitive impairment; One carbon metabolism

Indexed keywords

APOLIPOPROTEIN E; CHROMOGRANIN A; HOMOCYSTEINE; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; CARBON DIOXIDE FIXATION; CEREBROSPINAL FLUID; COGNITIVE DEFECT; EARLY DIAGNOSIS; GENETIC RISK; HUMAN; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL;

AGING; ALZHEIMER DISEASE; ATROPHY; BIOLOGICAL MARKERS; BRAIN; COGNITION DISORDERS; DIAGNOSTIC IMAGING; HUMANS; TIME FACTORS;

EID: 0031768722     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007020050094     Document Type: Article

References (47)

1. Andreasen N, Davidsson P, Hesse C, Lidström AM, Van de Voorde A, Vanmechelen E, Winblad B, Blennow K (1997) A community-based follow-up study on CSF tau protein in patients with dementia. In: Iqbal K, Winblad B, Nishimura T, Takeda M, Wisniewski HM (eds) Alzheimer's disease: biology diagnosis and therapeutics. John Wiley & Sons, Chichester, pp 149-154
2. Andreasen N, Hesse C, Davidsson P, Wallin A, Minthon L, Winblad B, Vanderstichele H, Vanmechelen E, Blennow K (1998a) Cerebrospinal fluid β-amyloid (1-42) in Alzheimer's disease: differences between early and late-onset AD and stability during the course of disease. Arch Neurol (in press)
3. Andreasen N, Vanmechelen E, Van de Voorde A, Davidsson P, Hesse C, Tarvonen S, Räihä I, Sourander L, Winblad B, Blennow K (1998b) Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community-based follow-up study. J Neurol Neurosurg Psychiatry 64: 298-305
4. Blennow K, Gottfries CG (1997) Neurochemistry of aging. In: Nelson JC (ed) Geriatric psychopharmacology. Marcel Dekker, New York, pp 1-27
5. Blennow K, Davidsson P, Wallin A, Fredman P, Gottfries CG, Månsson JE, Svennerholm L (1992) Differences in cerebrospinal fluid gangliosides between "probable Alzheimer's disease" and normal aging. Aging Clin Exp Res 4: 301-306
6. Blennow K, Wallin A, Gottfries CG (1993) Cerebrospinal fluid markers for Alzheimer's disease. In: Wolters EC, Scheltens Ph (eds) Alzheimer's disease: back to the future. ICG Printing, Dordrecht, pp 29-38
7. Blennow K, Davidsson P, Wallin A, Gottfries CG, Svennerholm L (1994) Ubiquitin in cerebrospinal fluid in Alzheimer's disease and vascular dementia. Int Psychogeriatr 6: 13-22
8. Blennow K, Davidsson P, Wallin A, Ekman R (1995a) Chromogranin A in cerebrospinal fluid: a biochemical marker for synaptic degeneration in Alzheimer's disease? Dementia 6: 306-311
9. Blennow K, Wallin A, Ågren H, Spenger C, Siegfried J, Vanmechelen E (1995b) Tau protein in cerebrospinal fluid: a biochemical diagnostic marker for axonal degeneration in Alzheimer's disease? Mol Chem Neuropathol 26: 231-245
10. Blennow K, Bogdanovic N, Alafuzoff I, Ekman R, Davidsson P (1996) Synaptic pathology in Alzheimer's disease: relation to severity of dementia, but not to senile plaques, neurofibrillary tangles or the ApoE-4 allele. J Neural Transm [P-D Sect] 103: 603-618
11. Brose N, Petrenko AG, Südhof TC, Jahn R (1992) Synaptotagmin, a CA + + sensor on the synaptic vesicle surface. Science 256: 1021-1025
12. Brosseau T, Legrain S, Berr C, Gourlet V, Vidal O, Amouyel P (1994) Confirmation of the epsilon 4 allele of the apolipoprotein E gene as a risk factor for late-onset Alzheimer's disease. Neurology 44: 342-344
13. Chiu E (1994) What in a name - dementia or dysmentia? (Editorial) Int J Geriatr Psychiatry 9: 1-4
14. Clarke ER, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I (1991) Hypohomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 324: 1149-1155
15. Davidsson P, Blennow K (1998) Neurochemical dissection of synaptic pathology in Alzheimer's disease. Int Psychogeriatr 10(1)
16. Davidsson P, Jahn R, Bergquist J, Ekman R, Blennow K (1996) Synaptotagmin, a synaptic vesicle protein, is present in human cerebrospinal fluid: a new biochemical marker for synaptic pathology in Alzheimer's disease? Mol Chem Neuropathol 27: 195-210
17. Davidsson P, Jahn R, Bergquist J, Ekman R, Blennow K (1996) Synaptotagmin, a synaptic vesicle protein, is present in human cerebrospinal fluid: a new biological marker for synaptic pathology in Alzheimer's disease? Mol Chem Neuropathol 27: 195-210
18. Davidsson P, Ekman R, Blennow K (1997) A new procedure for detecting brain-specific proteins in cerebrospinal fluid. J Neural Transm 104: 711-720
19. Folstein M, Folstein S, McHugh P (1975) "Mini-Mental State". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198
20. Goodwin JS, Goodwin JM, Gerry TJ (1983) Association between nutritional status and cognitive functioning in a healthy elderly population. J Am Med Assoc 249: 2917-2921
21. Gottfries CG (1990) Neurochemical aspects on aging and diseases with cognitive impairment. J Neurosci Res 27: 541-547
22. Green RC, Clarke VC, Thompson NJ, Woodard JL, Letz R (1997) Early detection of Alzheimer disease: methods, markers and misgivings. Alzheimer Dis Assoc Disord 11 [Suppl 5]: 1-5
23. Hakola HPA (1997) Benton's visual retention test in patients with polycystic lipomembraneous dysplasia with sclerosing leukoencephalopathy. Dementia Geriatr Cogn Disord 9: 38-42
24. Hardy J, Allsop D (1991) Amyloid deposition as the central event in the etiology of Alzheimer's disease. Trends Pharmacol Sci 12: 383-388
25. Jahn R, Südhof TC (1993) Synaptic vesicle traffic: rush hour in the nerve terminal. J Neurochem 61: 12-21
26. Joachim CL, Selkoe DJ (1992) The seminal role of the β-amyloid in the pathogeneis of Alzheimer's disease. Alzheimer Dis Assoc Disord 6: 7-34
27. Joborn C (1988) Primary hyperparathyroidism: psychiatric and muscular manifestations. Thesis, Uppsala University, Sweden
28. Joosten E, van den Berg A, Rietzler R, Naurath HJ, Lindenbaum J, Stabler S, Allen RH (1993) Metabolic evidence that deficiency of vitamin B12 (cobalamin), folate and vitamin B6 occur commonly in elderly people. Am J Clin Nutr 58: 468-476
29. Katzman R, Terry R (1993) The neurology of aging. FA Davis, Philadelphia
30. Khachaturian Z (1992) The five-five, ten-ten plan for Alzheimer disease. Neurobiol Aging 13: 197-198
31. Lehmann W, Gottfries CG, Regland B (1997) Identification of cognitive impairment in the elderly: homocysteine is an early marker. Dementia Geriatr Cogn Disord (in press)
32. Letz R, Green RC, Woodard JL (1996) Development of a computer-based battery designed to screen adults for neuropsychological impairment. Neurotoxicol Teratol 18:365-370
33. Linn RT, Wolf PA, Bachman DL, Knoefel JE, Cobb JL, Belanger AJ, Kaplan EF, D'Agostino RB (1995) The "preclinical phase" of probable Alzheimer's disease. Arch Neurol 52: 485-490
34. Martin D, Francis J, Protetch I, Huff FJ (1992) Time dependency of cognitive recovery with cobalamin replacement: report of a pilot study. J Am Geriatr Soc 40: 168-172
35. Masters CL, Beyreuther K (1994) Strategic thoughts on the Alzheimer's disease. Amyloid protein precursor: the way forward. In: Masters CL, Beyreuther K, Trillet M, Christen Y (eds) Amyloid protein precursor in development, aging and Alzheimer's disease. Springer, Berlin Heidelberg New York Tokyo, pp 1, 8
36. McCaddon A, Regland B, Fear C (1995) Trypsin inhibition: a potential cause of cobalamin deficiency common to the pathogenesis of Alzheimer-type dementia and AIDS dementia complex? Med Hypotheses 45: 200-204
37. McCaddon A, Davies G, Hudson P, Tandy S, Cattell H (1998) Total serum homocysteine in senile dementia of Alzheimer type. Int J Geriatr Psychiatry 13: 235-239
38. Metz J, Bel I AH, App B, Flicker L (1996) The significance of subnormal serum vitamin 12 concentration in older people: a case control study. J Am Geriatr Soc 44: 1355-1363
39. Naurath HJ, Joosten E, Riezler R, Stabler SP, Alien RH, Lindenbaum J (1995) Effects of vitamin B12, folate, and vitamin B6 supplements in elderly people with normal serum vitamin concentrations. Lancet 346: 85-89
40. Palmer AM, Bowen DM (1990) Neurochemical basis of dementia in the Alzheimer type: contribution of postmortem and antemortem studies. In: Fowler CJ, Carlson LA, Gottfries CG, Winblad B (eds) Biological markers in dementia of Alzheimer type. Smith-Gordon, Nishimura, pp 89-105
41. Rubin EH, Morris JC, Grant EA, Vendegna T (1989) Very mild senile dementia of the Alzheimer type. 1. Clinical assessment. Arch Neurol 46: 379-382
42. Sanan DA, Weisgraber KH, Russel SJ, Mahley RW, Huang D, Saunders A, Schmedel D, Wisniewski T, Frangione B, Rloses AD, Strittmatter WJ (1994) Apolipoprotein E associates with β amyloid peptide of Alzheimer's disease to form monofibrils. J Clin Invest 94: 860-869
43. Selhub J, Jaques PF, Wilson PWF, Rush B, Rosenberg IH (1993) Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. J Am Med Assoc 270: 2693-2698
44. Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak-Vance M, Schmedel D, Saunders AM, Goldgaber D, Roses AD (1993) Binding of human apolipoprotein E to synthetic amyloid β peptide: isoform-specific effects and implications for late-onset Alzheimer's disease. Proc Natl Acad Sci USA 90: 1977-1981
45. Terry RD, Masliah E, Salmon DP, Butters N, De Teresa R, Hill R, Hansen LA, Katzman R (1991) Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30: 572-580
46. Walch-Solimena C, Takei K, Marek KL, Midyett K, Südhof TC et al. (1933) Synaptotagmin: a membrane constituent of neuropeptide-containing large dense core vesicles. J Neurosci 13: 3895-3903
47. Wallin A (1989) Vascular dementia - pathogenetic and clinical aspects. Thesis, Göteborg University, Sweden